APP and Alzheimer disease: Overall, our data support a role of APP (T668) phosphorylation in the NGF‐driven control of amyloidogenesis in the basal forebrain and suggest early‐downstream effectors of the NGF pathway as targets in the development of novel anti‐amyloidogenic therapies for AD.